ANDROGRAPHIS POWDER

Andrographis paniculata, widely recognized as "King of Bitters" or "Kalmegh," is a revered herbaceous plant with a long and distinguished history in traditional medicine systems, particularly Ayurveda and Traditional Chinese Medicine (TCM). Native to South Asian countries such as India, Sri Lanka, and Pakistan, this annual plant is characterized by its intensely bitter taste, a hallmark of its potent phytochemical composition. Historically, Andrographis has been utilized for a broad spectrum of health concerns, primarily focusing on general wellness, immune system modulation, and supporting the body's natural defenses against environmental stressors. Its traditional applications underscore its perceived efficacy in maintaining overall health, especially during seasonal challenges, making it a foundational botanical in many herbal pharmacopeias globally for centuries.

The therapeutic efficacy of Andrographis is predominantly attributed to its rich array of bioactive diterpenoid lactones, collectively known as andrographolides. Key compounds include andrographolide, neoandrographolide, and deoxyandrographolide, which are extensively studied for their multifaceted pharmacological activities. Research indicates these compounds exert significant anti-inflammatory, antiviral, and antioxidant effects, alongside notable immunomodulatory properties. The mechanisms of action involve the modulation of various cellular signaling pathways, such as the suppression of NF-κB activation, a central regulator of inflammatory responses. This molecular interaction contributes to its traditional use in supporting respiratory health and mitigating inflammatory processes, as evidenced by studies demonstrating its potential to alleviate symptoms associated with upper respiratory tract infections.

Andrographis powder is a versatile ingredient widely incorporated into dietary supplements, herbal remedies, and functional food formulations. For optimal efficacy and consistency, Andrographis extracts are frequently standardized to a specific percentage of andrographolides, typically ranging from 10% to 30%, ensuring a consistent delivery of its primary active compounds. Clinical research, including meta-analyses and randomized controlled trials, provides evidence supporting its role in reducing the severity and duration of symptoms associated with common colds and uncomplicated upper respiratory tract infections. For instance, a systematic review published in *The Lancet* highlighted its potential benefits. Quality considerations for Andrographis powder include stringent sourcing, purity testing for heavy metals and contaminants, and adherence to Good Manufacturing Practices (GMP) to ensure product safety and efficacy for consumer applications.